Guided Therapeutics (GTHP) Current Deferred Revenue (2010 - 2025)

Guided Therapeutics has disclosed Current Deferred Revenue across 16 years of filings, most recently posting $189000.0 for Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $189000.0, down 77.74% year-over-year; the trailing twelve-month figure through Dec 2025 was $189000.0 (down 77.74% YoY), and the FY2025 annual result was $189000.0, down 77.74% from the prior year.
• Current Deferred Revenue came in at $189000.0 for Q4 2025 at Guided Therapeutics, down from $689318.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $278.0 million in Q3 2021 to a low of $62000.0 in Q1 2021.
• The 5-year median for Current Deferred Revenue is $511050.5 (2022), against an average of $14.4 million.
• Across the five-year window, Current Deferred Revenue jumped 661804.76% in 2021 and slumped 99.82% in 2022, its largest moves.
• Guided Therapeutics' Current Deferred Revenue stood at $337315.0 in 2021, then jumped by 50.93% to $509101.0 in 2022, then slipped by 16.67% to $424225.0 in 2023, then jumped by 100.11% to $848917.0 in 2024, then tumbled by 77.74% to $189000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $189000.0 (Q4 2025), $689318.0 (Q3 2025), and $679318.0 (Q2 2025), per Business Quant data.